Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Tim Van Hauwermeiren
|
| gptkbp:collaboratedWith |
gptkb:Zai_Lab
gptkb:Halozyme_Therapeutics Cilag GmbH International |
| gptkbp:focusesOn |
oncology
autoimmune diseases |
| gptkbp:foundedBy |
Hans de Haard
Tim Van Hauwermeiren Torsten Dreier |
| gptkbp:foundedIn |
2008
|
| gptkbp:headquartersLocation |
gptkb:Ghent,_Belgium
|
| https://www.w3.org/2000/01/rdf-schema#label |
argenx
|
| gptkbp:industry |
biopharmaceuticals
|
| gptkbp:listedOn |
gptkb:Euronext_Brussels
gptkb:NASDAQ |
| gptkbp:notableProduct |
Vyvgart
|
| gptkbp:numberOfEmployees |
over 600
|
| gptkbp:platform |
SIMPLE Antibody™ platform
|
| gptkbp:researchArea |
immunology
rare diseases |
| gptkbp:stockSymbol |
ARGX
|
| gptkbp:VyvgartApprovedFor |
generalized myasthenia gravis
|
| gptkbp:VyvgartApprovedIn |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:website |
https://www.argenx.com/
|
| gptkbp:bfsParent |
gptkb:Baker_Bros._Advisors
|
| gptkbp:bfsLayer |
7
|